 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Senl_H19x22P / SenlangBio, Senl_22 / SenlangBio
New P1 trial, CAR T-Cell Therapy: Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Nov 12, 2020
P1, N=50, Recruiting, Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
- ||| Senl_H19x22P / SenlangBio, Senl_22 / SenlangBio
New P1 trial, CAR T-Cell Therapy: CAR-T Cells in Treating Patients With Relapsed or Refractory NHL (clinicaltrials.gov) - Nov 12, 2020
P1, N=100, Recruiting, Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
- || Senl_H19x22P / SenlangBio, Senl_22 / SenlangBio
New P1 trial, CAR T-Cell Therapy: CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 12, 2020
P1, N=50, Recruiting, Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
- ||| Senl_22 / Avalon GloboCare
New trial, CAR T-Cell Therapy: Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 14, 2020
P=N/A, N=20, Recruiting, Sponsor: Hebei Senlang Biotechnology Inc., Ltd.